Hepatitis C prevalence in a priority municipality for tuberculosis: single center study
DOI:
https://doi.org/10.5902/2236583472042Keywords:
Tuberculosis, Hepatitis C, PrevalenceAbstract
Objective: Hepatitis C virus (HCV) infection could be a risk factor for the development of active tuberculosis (TB) and, despite the proven prevalence of tuberculosis/hepatitis C (TB/HCV) co-infection, there are still few studies addressing this relationship. The aim of the present study was to assess the prevalence of hepatitis C in patients with TB and its association with clinical and epidemiological data. Methods: Patients with TB (n=34), older than 18 years, of both genders, were studied. Anti-HCV antibodies were evaluated by ELISA and the clinical and epidemiological data were obtained from medical records. Analyzes were performed using Fisher and Mann-Whitney tests (p<0.05). Results: Among the 34 TB patients assessed, 3 had anti-HCV antibodies demonstrating a seroprevalence of 8.82%. There was no association of TB/HCV with clinical and epidemiological data in the studied population. Final Considerations: Due to the association TB/HCV being a reality, the introduction of a routine screening for hepatitis C markers before antituberculosis treatment would be recommended for a better follow-up of patients and reduced risk of hepatotoxicity.
Downloads
References
Global tuberculosis report 2020 [Internet]. [citado 5 de setembro de 2022]. Disponível em: https://www.who.int/publications-detail-redirect/9789240013131
Churchyard G, Kim P, Shah NS, Rustomjee R, Gandhi N, Mathema B, et al. What We Know About Tuberculosis Transmission: An Overview. J Infect Dis. 3 de novembro de 2017;216(suppl_6):S629–35.
Nogueira AF, Facchinetti V, Souza MVN de, Vasconcelos TRA. Tuberculose: uma abordagem geral dos principais aspectos. Tuberculosis: a general approach of the main aspects [Internet]. 2012 [citado 5 de setembro de 2022]; Disponível em: https://www.arca.fiocruz.br/handle/icict/37745
Kozakevich GV, Silva RM da. TUBERCULOSE: REVISÃO DE LITERATURA. Arq Catarin Med. 2015;44(4):34–47.
de Martino M, Lodi L, Galli L, Chiappini E. Immune Response to Mycobacterium tuberculosis: A Narrative Review. Front Pediatr [Internet]. 2019 [citado 5 de setembro de 2022];7. Disponível em: https://www.frontiersin.org/articles/10.3389/fped.2019.00350
Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. abril de 2018;44:145–52.
Wu PH, Lin YT, Hsieh KP, Chuang HY, Sheu CC. Hepatitis C Virus Infection Is Associated With an Increased Risk of Active Tuberculosis Disease. Medicine (Baltimore). 21 de agosto de 2015;94(33):e1328.
Awofeso N. Prisons as Social Determinants of Hepatitis C Virus and Tuberculosis Infections. Public Health Rep. 1o de julho de 2010;125(4_suppl):25–33.
Beijer U, Wolf A, Fazel S. Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis. Lancet Infect Dis. 1o de novembro de 2012;12(11):859–70.
Reis NRS, Lopes CLR, Teles SA, Matos MAD, Carneiro MAS, Marinho TA, et al. Hepatitis C virus infection in patients with tuberculosis in Central Brazil. Int J Tuberc Lung Dis. 1o de outubro de 2011;15(10):1397–402.
Behzadifar M, Heydarvand S, Behzadifar M, Bragazzi NL. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci [Internet]. 2019 [citado 5 de setembro de 2022];29(1). Disponível em: https://www.ajol.info/index.php/ejhs/article/view/187207
São Paulo, State Government (2017) State Plan for the Elimination of Tuberculosis: 2018 to 2021 Tuberculosis Control Program of the State of São Paulo. São Paulo, 1-9.
Costi C, Grandi T, Halon ML, Silva MSN, Silva CMD da, Gregianini TS, et al. Prevalence of hepatitis C virus and human immunodeficiency virus in a group of patients newly diagnosed with active tuberculosis in Porto Alegre, Southern Brazil. Mem Inst Oswaldo Cruz. abril de 2017;112:255–9.
Teixeira LMM, Silva MR, Gomide CP, da Costa RR. Ocorrência da Hepatite C entre pacientes portadores de micobacterioses atendidos em centros de referências de Juiz de Fora. 2014.
Feleke BE, Feleke TE, Adane WG, Girma A. Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study. Virol J. 23 de julho de 2020;17(1):113.
Getie B, Ayalew G, Amsalu A, Ferede G, Yismaw G, Tessema B. Seroprevalence and Associated Factors of Hepatitis B and C Virus Among Pulmonary Tuberculosis Patients Attending Health Facilities in Gondar Town, Northwest Ethiopia. Infect Drug Resist. 3 de setembro de 2021;14:3599–608.
Merza MA, Haji SM, Alsharafani AMH, Muhammed SU. Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan: Are HBsAg and anti-HCV prerequisite screening parameters in tuberculosis control program? Int J Mycobacteriology. 1o de setembro de 2016;5(3):313–7.
Agha MA, El-Mahalawy II, Seleem HM, Helwa MA. Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity. Egypt J Chest Dis Tuberc. 1o de janeiro de 2015;64(1):91–6.
Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, et al. Impaired Allostimulatory Capacity of Peripheral Blood Dendritic Cells Recovered from Hepatitis C Virus-Infected Individuals. J Immunol. 1o de maio de 1999;162(9):5584–91.
Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, et al. Hepatitis C Virus Core Protein Binds to the Cytoplasmic Domain of Tumor Necrosis Factor (TNF) Receptor 1 and Enhances TNF-Induced Apoptosis. J Virol. maio de 1998;72(5):3691–7.
El-Mokhtar MA, Elgendy SG, Eldin AS, Hassan EA, Hasan AAA, Abdel Hameed MR, et al. Hepatitis C Virus Affects Tuberculosis-Specific T Cells in HIV-Negative Patients. Viruses. janeiro de 2020;12(1):101.
Rabahi MF, Silva JLR da, Ferreira ACG, Tannus-Silva DGS, Conde MB. Tuberculosis treatment. J Bras Pneumol. dezembro de 2017;43:472–86.
BRAZIL. Ministry of Health. (2019). Health Surveillance Department. Department of Communicable Disease Surveillance. Manual of Recommendations for Tuberculosis Control in Brazil / Ministry of Health, Department of Health Surveillance, Department of Communicable Disease Surveillance. – Brasilia: Ministry of Health.
Lima M de FS de, Melo HRL de. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saúde Pública. abril de 2012;28:698–708.
Pereira FM (2019). Infection rate of human cell lymphotropic virus (HTLV), hepatitis C virus (HCV), HTLV/HCV co-infection in the State of Bahia and impact of HTLV/HCV co-infection on cytokine profile. Doctoral thesis. Oswaldo Cruz Foundation. Goncalo Moniz Institute.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Eliana Peresi-Lordelo, Aline Cintra Nemer Diório, Ana Carolina Munuera Pereira, Bruna Alves Martins, Bruno Kenji Kito, Fernando Nunes Gavioli Boni, Yara Felippe Bueno Croscioli, Paulo José Mascarenhas Mazaro, João Guilherme Araujo Matarazo, Priscila Paulin
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
A Declaração de Direito Autoral e os itens a serem observados podem ser visualizados no seguinte link: http://cascavel.ufsm.br/revistas/ojs-2.2.2/index.php/seculoxxi/information/sampleCopyrightWording